Phase II study of neoadjuvant chemotherapy with SOX + bevacizumab in patients with locally advanced rectal cancer - Phase II study of neoadjuvant chemotherapy with SOX + bevacizumab in patients with locally advanced rectal cancer

Asahikawa Medical University0 个研究点目标入组 40 人开始时间: 2014年10月2日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Any distant metastases 2) Neurological disorder by cerebrovascular disorder within a year before enrollment 3) Symptomatic heart disease or heart disease requiring treatment. Cardiac infarction within a year before enrollment 4) Pleural, peritoneal and pericardial effusion 5) Prior systematic chemotherapy, pelvic irradiation and/or surgery for malignant tumor 6) Active double cancer. Asynchronous double cancer with disease-free duration of 5 years or less. (Including colorectal cancer) 7) Interstitial pneumonia or pulmonary fibrosis 8) Poorly controlled infection 9) Grade 2 or worse peripheral neuropathy 10) Bowel obstruction (Patients with diverting stoma are allowed for enrollment) 11) Poorly controlled diarrhea 12) Confirmed or possible pregnancy, lactation, willingness to become pregnant (for women), or willingness to have a child (for men) 13) Contraindication of bevacizumab 14) Physician concludes that the patient's participation in this trial is inappropriate.

发起方